Brokerages Set Immunome, Inc. (NASDAQ:IMNM) Price Target at $29.80

Shares of Immunome, Inc. (NASDAQ:IMNM) have been assigned an average rating of “Buy” from the seven ratings firms that are covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have covered the stock in the last year is $29.80.

IMNM has been the topic of several research reports. Guggenheim began coverage on shares of Immunome in a research report on Monday, April 15th. They set a “buy” rating and a $35.00 price objective on the stock. Piper Sandler started coverage on Immunome in a research report on Friday, May 31st. They set an “overweight” rating and a $27.00 price objective for the company. Wedbush reissued an “outperform” rating and issued a $33.00 target price on shares of Immunome in a report on Tuesday, May 14th. Finally, JPMorgan Chase & Co. began coverage on shares of Immunome in a research report on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 price objective on the stock.

Insiders Place Their Bets

In related news, Director Jean Jacques Bienaime bought 2,000 shares of the firm’s stock in a transaction on Tuesday, May 21st. The shares were bought at an average cost of $13.57 per share, for a total transaction of $27,140.00. Following the transaction, the director now owns 9,615 shares of the company’s stock, valued at $130,475.55. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 8.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Immunome

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Cerity Partners LLC purchased a new position in Immunome in the 4th quarter valued at approximately $656,000. Mayo Clinic acquired a new position in shares of Immunome during the 4th quarter worth $1,161,000. Emfo LLC acquired a new position in shares of Immunome during the 4th quarter worth $633,000. Acadian Asset Management LLC purchased a new stake in shares of Immunome in the 3rd quarter worth about $414,000. Finally, Jump Financial LLC acquired a new stake in Immunome in the 4th quarter valued at about $172,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Stock Performance

Immunome stock opened at $16.05 on Tuesday. The company has a market capitalization of $962.52 million, a P/E ratio of -2.13 and a beta of 1.85. Immunome has a fifty-two week low of $4.76 and a fifty-two week high of $30.96. The stock has a 50-day simple moving average of $16.08 and a 200-day simple moving average of $16.58.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.46. The company had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $4.00 million. Immunome had a negative return on equity of 37.33% and a negative net margin of 1,829.44%. As a group, analysts forecast that Immunome will post -1.45 earnings per share for the current year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.